News About Lucy Biotech
Through science, we discover, advance, and translate knowledge into technology.
ENCell and Lucy Biotech Form a Strategic Alliance
September 9, 2024
Lucy Biotech has formed a strategic alliance with ENCell where ENCell will have access to Lucy Biotech's cutting edge cryopreservation technology for its future MSC therapeutics development while Lucy Biotech will be given exclsuive licesne to commercialize its lead MSC therapy EN001 for six key Asian markets, including Hong Kong, Taiwan, Macau, Vietnam, Thailand, and Singapore. Lucy Biotech is also given the exclusive option to license EN001 for China region provided certain financial conditions are met.  EN001 is a cutting-edge mesenchymal stem cell therapy developed by ENCell, aimed at treating conditions involving nerve and muscle degeneration. Derived from Wharton's Jelly mesenchymal stem cells, EN001 has shown significant potential in preclinical studies for regenerating damaged tissues. It is currently in clinical trials for Charcot-Marie-Tooth disease type 1A, with further trials planned for Duchenne muscular dystrophy and sarcopenia. As a promising therapeutic candidate, EN001 represents a new frontier in regenerative medicine, offering hope for patients with debilitating diseases. ENCell is a leading force in the biotechnology field, known for its cutting-edge work in developing next-generation therapies. A clinical-stage company, ENCell has a strong pipeline, with EN001 being one of its flagship projects. EN001, developed from early-stage mesenchymal stem cells, has shown promising results in preclinical studies, demonstrating its potential in regenerating damaged nerves and muscles. The company has successfully completed Phase 1a clinical trials for Charcot-Marie-Tooth disease and is advancing into Phase 1b trials. With regulatory approvals for additional clinical trials targeting Duchenne muscular dystrophy and sarcopenia, ENCell continues to push the boundaries of regenerative medicine, making it a key player in the global biotech market.
City University of Hong Kong and Lucy Biotech Announce Partnership Research Programme Funding Grant to Advance Novel Cell Therapy for Neurodegenerative Diseases
August 15, 2024
Lucy Biotech, in collaboration with Professor Jessica Ai-jia Liu from the Department of Neuroscience at City University of Hong Kong (CityU), proudly announced the approval of a Partnership Research Programme Funding Grant to support the development of a groundbreaking cell therapy aimed at treating neurodegenerative diseases. This innovative approach utilizes reprogrammed stem cells derived from urine to create new therapeutic avenues. ​Professor Jessica Ai-jia Liu, a distinguished neuroscientist at CityU, is renowned for her pioneering work in stem cell biology and regenerative medicine, particularly in developing novel therapeutic strategies for neurodegenerative diseases. Her research focuses on understanding neural development and utilizing stem cell technology to promote neural regeneration. Under this collaboration, Lucy Biotech will develop engineered cell-permeable transcription factors to reprogram stem cells into neuroprogenitor cells and formulate advanced cryopreservation solutions to preserve these cells effectively. Professor Liu will utilize these cutting-edge tools for the preclinical development of urine-derived stem cells, exploring their potential to treat various diseases where neuroprogenitor cells may offer significant therapeutic benefits. City University of Hong Kong (CityU) is a leading public research university located in Kowloon, Hong Kong. Established in 1984, CityU is known for its dynamic and innovative approach to education and research, emphasizing interdisciplinary studies, cutting-edge technology, and global engagement. The university offers a wide range of undergraduate and postgraduate programs across various disciplines, including science, engineering, business, law, and social sciences. With a strong focus on fostering creativity and entrepreneurship, CityU is dedicated to nurturing talent and driving forward innovation that contributes to the development of Hong Kong and the broader global community.
Lucy Biotech and Guoke Ningbo Life Science Institute Forge Strategic Partnership to Advance Organ Cryopreservation Technology
January 30, 2024
Lucy Biotech and the Guoke Ningbo Life Science and Health Industry Research Institute have signed a Memorandum of Understanding (MOU) to establish a strategic research collaboration aimed at advancing organ cryopreservation technology. This partnership marks a significant step forward in combining the expertise and resources of both organizations to accelerate breakthroughs in this critical field. The MOU sets the framework for ongoing discussions and communications to define joint research objectives, outline specific research activities, and delineate responsibilities, ensuring a robust and focused approach to achieving impactful scientific outcomes. Guoke Ningbo Life Science and Health Industry Research Institute is a research institute based in Ningbo, China, focused on life sciences and the health industry. The institute aims to advance scientific research and innovation in areas such as biotechnology, pharmaceuticals, and medical devices. It collaborates with academic institutions, industry partners, and government agencies to drive the development of health-related technologies and applications. The institute is committed to fostering a vibrant ecosystem for life sciences and health innovation, supporting the commercialization of scientific discoveries, and contributing to the overall growth of the health industry in the region.
Lucy Biotech Joins HKSTP Incubios Program: A Launchpad for Innovation
September 1, 2023
The HKSTP Incubios program is a highly competitive initiative that rigorously evaluates new venture ideas and teams. Expert panels composed of business entrepreneurs and scientists with domain expertise review each application in detail. After more than a year of evaluation, including presentations and due diligence, Lucy Biotech has been officially accepted into the program. This acceptance grants the company HKD $6 million in financial support, office and lab space within state-of-the-art facilities at the Hong Kong Science and Technology Park (HKSTP), and access to advanced laboratory equipment. Additionally, Lucy Biotech will benefit from mentorship opportunities and a well-connected venture financing network, providing a strong foundation to accelerate its innovative ventures. The Hong Kong Science Park, located in Pak Shek Kok, New Territories, overlooks the Tolo Harbour waterfront and is close to the Chinese University of Hong Kong. Administered by the Hong Kong Science and Technology Parks Corporation, a statutory body founded in 2001, the park spans 330,000 square meters and provides a campus-like environment tailored for high-technology enterprises. It accommodates companies of all sizes and stages of development, fostering interaction and innovation both locally and globally. The park’s key goals include diversifying Hong Kong’s economy, expanding employment opportunities, elevating the city’s global tech status, fostering STEM talent, and contributing to a sustainable and brighter future for the next generation.